MedPath

LEXISCAN(R) (REGADENOSON)

LEXISCAN(R) (REGADENOSON) INJECTION 0.4mg/5mL (0.08 mg/mL) 5mL SYR

Approved
Approval ID

99640071-4db2-9317-e053-2995a90a610d

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 28, 2024

Manufacturers
FDA

HF Acquisition Co LLC, DBA HealthFirst

DUNS: 045657305

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

LEXISCAN(R) (REGADENOSON)

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code51662-1448
Application NumberNDA022161
Product Classification
M
Marketing Category
C73594
G
Generic Name
LEXISCAN(R) (REGADENOSON)
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateJanuary 28, 2024
FDA Product Classification

INGREDIENTS (1)

REGADENOSONActive
Quantity: 0.08 mg in 1 mL
Code: 2XLN4Y044H
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LEXISCAN(R) (REGADENOSON) - FDA Drug Approval Details